about
Obesity and cancer: mechanistic insights from transdisciplinary studiesCOX-2 and cancer: a new approach to an old problemInflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequencesCOX2 genetic variation, NSAIDs, and advanced prostate cancer riskCombination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyAlterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinomaα-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutationAnti-inflammatory activity of soy and tea in prostate cancer prevention2-(4-Chlorophenyl)benzo-1,4-quinone induced ROS-signaling inhibits proliferation in human non-malignant prostate epithelial cellsEffect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data.Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceEffect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis.Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma.Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.An observational study on the expression of cyclooxygenase-2 in meningioma.Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.Celecoxib: a specific COX-2 inhibitor with anticancer properties.A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred DiethylstilbestrolAspirin and urologic cancer risk: an update.Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinomaOverexpression of COX-2 in oral squamous cell carcinoma patients undergoing chemoradiotherapyα(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line.Management of prostate cancer. Part 1: chemoprevention.Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.COX-2 inhibition: a possible role in the management of prostate cancer?TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model.Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer.Cyclooxygenase-2 in cancer and angiogenesis.Role of the prostaglandin pathway and the use of NSAIDs in genitourinary malignancies.Inflammation and cancer: how friendly is the relationship for cancer patients?The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancerRoles of Eicosanoids in Prostate Cancer.
P2860
Q26786829-FEE9AEE2-2BDB-4368-BCD5-47E882EEEB81Q28191533-EEF39945-3F70-4D78-96E3-1B6C721E1CFAQ28193430-962C59BF-5B7A-483E-9DB9-E559EE6A5DAEQ28217972-DFCA60BF-7A14-43B0-8988-7100ED0F700BQ28218423-616D2026-FE71-4BA8-A481-B38539606907Q28360358-6086AC6E-AFE7-459B-976B-F0A627C92B4FQ28389681-1B063A8A-73C1-4739-B007-0AE73104D5E8Q28391888-066E03D7-3DDF-4168-86B3-1108B6D9B206Q28396322-BD128A24-62A9-4A70-9404-1446C31CE822Q30523968-6C67463D-3EE2-4FFC-991A-38EE8977D6A3Q31130013-161C6F05-6927-4D9F-B44E-B5A27773E5F6Q33304363-B5077AFF-3ED5-4804-9BE1-22199D29121EQ33579568-0FD8724C-E54E-4D21-8EB1-2A1AE7F21510Q33614082-B30FA152-FEF8-47A4-AE90-C9695D3EA324Q33659189-75B7CF7C-B564-4E0A-B443-4335ADFD2F06Q33752554-E1FF4A82-8B2F-411F-881B-99C4F62245D0Q34283636-51C40AFA-0351-41EC-A261-38202757B11DQ34447735-79367B0D-67DD-4EB5-BC51-8B70341A673CQ34536921-CA26E630-0CC5-4914-ADB3-88C5F0EA797BQ34608635-D49AA05E-70B9-420E-9CFA-FD48ACBEF2B0Q34627994-0938B309-0908-4B9E-BAC5-E6196BB7CE52Q34635300-44C3B352-478E-4420-83E2-139CBF09A90DQ34649327-DEC969BD-0172-442D-A156-DC2F97176FDCQ35011895-DA6676E6-8203-4D44-B049-AFB1DA6CB931Q35102355-5A64758A-A39D-4C38-B389-7AC13200B803Q35788745-4B1E433E-E70F-4F7F-B580-0EF808239863Q35831755-E36D7D4F-C726-458A-9071-AB295F4C6ACBQ35964178-F45A577D-D66D-44DE-B11D-6EC6D2E96A97Q36178536-53146D6F-A343-4F7D-8611-947F815DDF5DQ36407468-A850CF01-CE71-4D40-A7F2-466CE33949D2Q36649103-04CE74D6-C56C-4E88-9429-52AE6C1AF2B5Q36740041-E7FCE58D-29F6-496C-894D-09BD4A7D6875Q36771000-748D0CC5-59BF-44D1-8485-5978B6E63174Q37154651-605E39BA-291B-497A-A77D-F05330F0D436Q37155271-E14DB07F-0295-4F4D-BC66-4BE68A84A3EEQ37174279-049BADC0-C3BC-43C9-85F7-B282FE47B2FDQ37202773-16913D55-64D4-4379-9B09-919DC900DF7FQ37316105-EA0860B1-569F-4DA1-8BDD-9612ABF39D62Q37586958-1789252A-8CD9-449E-9771-0FBD1E3172BAQ37592857-B11D293D-EA60-41D5-974D-767E04B82C9E
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Expression of cyclooxygenase-2 in prostate carcinoma.
@en
Expression of cyclooxygenase-2 in prostate carcinoma.
@nl
type
label
Expression of cyclooxygenase-2 in prostate carcinoma.
@en
Expression of cyclooxygenase-2 in prostate carcinoma.
@nl
prefLabel
Expression of cyclooxygenase-2 in prostate carcinoma.
@en
Expression of cyclooxygenase-2 in prostate carcinoma.
@nl
P2093
P2860
P1433
P1476
Expression of cyclooxygenase-2 in prostate carcinoma.
@en
P2093
Kawamura M
Tsubouchi Y
Yoshimura N
Yoshimura R
P2860
P304
P356
10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C
P407
P50
P577
2000-08-01T00:00:00Z